ICML 2019 | Hello TELLOMAK: new trial for T-cell lymphoma

Pierluigi Porcu

Pierluigi Porcu, MD, Sidney Kimmel Cancer Center – Jefferson Health, Philadelphia, PA, discusses the current open-label, multicohort, multi-center, international Phase II TELLOMAK trial (NCT03902184), evaluating the anti-KIR3DL2 agent IPH4102 alone or with chemotherapy in advanced T-cell lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video